Childhood visual impairment and blindness: 5-year data from a tertiary low vision center in Israel

Yahalom, Claudia; Braun, Ron; Patal, Rani; Saadeh, Ibrahim; Blumenfeld, Anat; Macarov, Michal; Hendler, Karen

doi:10.1038/s41433-021-01743-3

Cited by 4 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the child, their family, and their clinicians, permanent loss of vision in both eyes is a tremendous shock, meaning a severe loss of function and a significant reduction in the child’s quality of life [ 16 ]. Therefore, saving as much vision as possible remains a necessity for children with malignancy.…”

Section: Discussionmentioning

confidence: 99%

Visual conservation treatment dilemmas in neuroblastoma with bilateral blindness

Cheng,

Lin,

Yang

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Objective To investigate the clinical features, treatment strategies, and prognosis of neuroblastoma with bilateral blindness. Methods The clinical data of five patients with bilateral blindness neuroblastoma admitted to Beijing Children’s Hospital from April 2018 to September 2020 were retrospectively collected to summarize their clinical characteristics. Results All patients were female and the median age at presentation was 25 (23, 41) months. The median intervention time from the onset of symptoms of bilateral blindness to the start of treatment was 10 (10, 12) days. All five cases were staged as stage M and grouped as high risk. Four cases were MYCN gene amplification and one case was MYCN acquisition. Five children were treated according to a high-risk neuroblastoma treatment protocol. Four children did not recover their vision after treatment, and one case improved to have light perception. All patients were effectively followed up for a median of 20 (12, 31) months, with three deaths, one tumor-free survival, and one recurrent tumor-bearing survival. Conclusion Neuroblastoma with bilateral blindness is rare in the clinic, mostly in children of young age, and is often associated with MYCN amplification and multiple metastases. Early hormone shock therapy and optic nerve decompression are beneficial for preserving the child’s vision. A joint multi-disciplinary treatment may help in the formulation of treatment decisions. Achieving a balance between good visual preservation and survival within the short optic nerve neurotherapeutic window is extremely challenging.

show abstract

Section: Discussionmentioning

confidence: 99%

Visual conservation treatment dilemmas in neuroblastoma with bilateral blindness

Cheng,

Lin,

Yang

et al. 2024

Discov Onc

View full text Add to dashboard Cite

show abstract

“…Regarding the inheritance pattern, previous studies showed a strong association between AD-inheritance RP and CME. 3,8,[12][13][14] Liew et al, made the assumption that relatively healthy retinal tissue is required to cause CME, which would explain why younger patients with milder forms of RP (such as AD disease) are more likely to have CME than more severe forms (X-linked RP). 8 In the current study, most of the patients included in our cohort harbored AR inheritance pattern (88%).…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…1 In the pediatric population, inherited eye diseases (mainly inherited retinal dystrophies) are also being described during the last decade as the most common causes for childhood blindness in developed countries. 2,3 Cystoid macular edema (CME) is considered a common feature in patients with retinal dystrophies. Usually, central vision may be preserved until late stages in the disease.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and associated factors of cystoid macular edema in children with early onset inherited retinal dystrophies

Ben-Avi

Rivera

Hendler

et al. 2022

European Journal of Ophthalmology

Self Cite

View full text Add to dashboard Cite

Purpose To assess the prevalence of Cystoid macular edema (CME) in children with early onset retinal dystrophies (EORD) and to evaluate if there are associated factors and/or response to early treatment. Methods Consecutive, retrospective case series. Medical records of patients, 18 years or younger, diagnosed with EORD were included in the study. Optic coherence tomography (OCT) scans, clinical and genetic characteristics as well as other associated factors were analyzed. Main outcome was the presence of CME on OCT scans. Results One hundred and two children with EORD (aged 1–18 years, mean 9.7 ± 4.2) were recruited. OCT was performed in 60/102 and among them, 19/60 had CME (31.7%). The disease-causing gene was identified in 13 children with CME; autosomal-recessive inheritance was found in 88.3% of those with an identified genotype. Children with Usher syndrome had CME in 44.4% of the cases. Early treatment of CME resulted in variable response. Conclusions Our results show that 31.7% of children with EORD who underwent OCT have macular edema. CME prevalence was found to be relatively higher in children with Usher syndrome. Autosomal recessive was the most prevalent inheritance identified in the EORD group as well as in the CME group. Additional prospective research is needed to assess the efficacy of early CME treatment in pediatric EORD patients.

show abstract

Rationale and protocol paper for the Asia Pacific Network for inherited eye diseases

Wong,

Tham,

Simunovic

et al. 2024

Asia-Pacific Journal of Ophthalmology

View full text Add to dashboard Cite

Childhood visual impairment and blindness: 5-year data from a tertiary low vision center in Israel

Cited by 4 publications

References 16 publications

Visual conservation treatment dilemmas in neuroblastoma with bilateral blindness

Visual conservation treatment dilemmas in neuroblastoma with bilateral blindness

Prevalence and associated factors of cystoid macular edema in children with early onset inherited retinal dystrophies

Rationale and protocol paper for the Asia Pacific Network for inherited eye diseases

Contact Info

Product

Resources

About